EIC Accelerator

The EIC Accelerator is the European Innovation Council's flagship funding for high-risk, high-potential startups and SMEs working on deep tech. It backs a single company, never a consortium, which sets it apart from most Horizon Europe calls, and it targets technologies sitting at Technology Readiness Levels 5 to 8: validated in the lab or field, but too risky for private investors to scale alone. The offer is blended finance: a non-dilutive grant of up to 2.5 million euros plus equity from the EIC Fund, typically 1 to 10 million euros and more through the STEP Scale-Up route. You can ask for grant-only, equity-only, or both. For 2026 the Commission allocated roughly 414 million euros to the Open call and 220 million to thematic Challenges, around 634 million in total. The funded look concrete, not abstract. Companies like Alvus, building a full biomethane value chain from farm residues, fight-dm1, developing a first-in-class therapy for myotonic dystrophy, and PAH-Advance, advancing a drug for pulmonary arterial hypertension, each took this route and secured the full 2.5 million euro grant. The catch is competition: end-to-end success runs near 3 percent, so a sharp, evidence-backed application is not optional.

• Non-dilutive grant of up to €2.5M
• Equity investment of up to €10M through the EIC Fund (up to €30M equity-only via STEP Scale-Up)
• Business Acceleration Services (mentoring, networking, investor matching)
• Access to EIC community of 4,000+ funded companies
• No sector restrictions — open to all deep tech verticals

This is built for a venture-backable deep tech company with a genuine technological breakthrough already validated in the lab or field (TRL 5 or higher) and a clear, capital-hungry path to scaling across Europe and beyond. If you have hard IP, early traction or pilot results, and you need both non-dilutive cash and patient equity to cross the gap that scares off private investors alone, few instruments anywhere match it. Hardware, biotech, climate tech, advanced materials, and similar capital-intensive innovations fit especially well. Honestly skip it if you are pre-product or still doing core research at TRL 1-4; that is Pathfinder territory, and the Accelerator will read you as too early. Skip it if your innovation is a software feature, a marketplace, or an incremental improvement on something that already exists, because evaluators are explicitly hunting for market-creating novelty and high technical risk. And if you cannot spare three to six months for a serious, evidence-heavy application across three stages, the roughly 3 percent end-to-end odds make a rushed attempt poor value for the time.